Karyopharm Therapeutics Inc (KPTI) — Cash Flow Reinvestment Rate
Latest as of December 2021:
1.20x
Karyopharm Therapeutics Inc (KPTI) has a Cash Flow Reinvestment Rate of 1.20x as of December 2021, reinvesting $30.68 Million (capex $207.00K plus investments $30.48 Million) from operating cash flow of $25.48 Million. See KPTI FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
1.20x
(Capex + Investments) / Operating CF
Total Reinvested
$30.68 Million
Capex + Investments
Operating Cash Flow
$25.48 Million
USD
Capital Expenditures
$207.00K
USD
Annual Cash Flow Reinvestment Rate for Karyopharm Therapeutics Inc (None–None)
Year-by-year capital reinvestment analysis for Karyopharm Therapeutics Inc. See KPTI financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow